4D Molecular Therapeutics logo

4D Molecular Therapeutics (FDMT) Q3 2024 Earnings

FDMT·Reported November 13, 2024·Before market open

4D Molecular Therapeutics reported Q3 2024 revenue of $3.0K, missed analyst consensus of $2.2M by $2.2M. Diluted EPS came in at $-0.79, missed the $-0.67 consensus by $0.12.

Revenue
$3.0Kmissed by $2.2M
Consensus: $2.2M
Diluted EPS
$-0.79missed by $0.12
Consensus: $-0.67
SEC

SEC Filings

Earnings release8-K not filed yet
Quarterly report10-Q · 0000950170-24-126370

Financial Snapshot

Trailing eight quarters through Q3 2024

View all metrics

Revenue

View metric

Net Income

View metric

Operating Cash Flow

View metric

EPS (Diluted)

View metric

Q3 2024 Earnings FAQ

Common questions about 4D Molecular Therapeutics's Q3 2024 earnings report.

4D Molecular Therapeutics (FDMT) reported Q3 2024 earnings on November 13, 2024 before market open.

4D Molecular Therapeutics reported revenue of $3.0K and diluted EPS of $-0.79 for Q3 2024.

Revenue missed the consensus estimate of $2.2M by $2.2M. EPS missed the consensus estimate of $-0.67 by $0.12.

You can read the 10-Q periodic report (0000950170-24-126370) directly on SEC EDGAR. The filing index links above go to sec.gov.